中文名：Rebastinib (DCC-2036)
英文名：Rebastinib (DCC-2036)
纯度：Moligand™，10mM in DMSO
货号：R408600
Cas号：1020172-07-9
存储温度：-80℃储存
运输条件：特低温运输
产品介绍：
Information
Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor forAbl1(WT)and Abl1(T315I) withIC50of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.
In vitro
DCC-2036 shows the potent inhibitory activities against purified native Abl1 in unphosphorylated (u-Abl1native) and phosphorylated (p-Abl1native) forms, unphosphorylated and phosphorylated gatekeeper mutant Abl1T315I, and the activation loop mutant Abl1H396P in a non-ATP-competitive manner with IC50 of 0.8 nM, 2 nM, 1.4 nM, 5 nM, and 4 nM, respectively. Moreover, DCC-2036 also inhibits the Src family kinases Src, LYN, FGR, and HCK, and the receptor TKs KDR, FLT3, and TIE2 with IC50 of 34 nM, 29 nM, 38 nM, 40 nM, 4 nM, 2 nM and 6 nM, respectively. DCC-2036 shows the anti-proliferative activities against Ba/F3 cells expressing native or mutant Bcr-Abl1 with IC50 ranging from 2 nM to 150 nM. In addition, DCC-2036 also inhibits proliferation of the Ph+ cell line K562 (IC50 5.5 nM), and induces apoptosis in both Bcr-Abl1-expressing Ba/F3 and K562 cells potently. A recent study shows that DCC-2036 shows the selectivity for growth inhibition of Bcr-Abl-positive cells by its marked inhibition of CML cell lines compared to non-CML leukemia lines.
In vivo
In a mouse allograft model bearing Ba/F3-Bcr-Abl1T315I leukemia cells, DCC-2036 treatment by oral gavage at 100 mg/kg once daily effectively inhibits Bcr-Abl1 signaling and significantly prolongs mouse survival.
Cell Data
cell lines：
Concentrations：0-10 μM
Incubation Time：72 hours
Powder Purity:≥99%
查看阿拉丁官网此产品相关对应页面：https://www.aladdin-e.com/zh_cn/R408600.html
关键字： 瑞巴替尼 (DCC-2036);1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea
阿拉丁（A股科创板上市企业，股票代码：688179） 是科研服务领域的领先供应商与制造商，拥有科学服务领域领导品牌：阿拉丁。核心业务涵盖高端化学与生化试剂、生命科学、小分子及化合物库及材料科学四大领域，并自主拥有“芯硅谷”实验耗材品牌，依托电商平台实现线上主导的销售模式 。产品广泛服务于985/211高校、科研院所及生物医药、化工材料等领域220余家A股上市公司。
国内以上海化工园区、奉贤基地为核心，建成超7.6万㎡现代化产业集群 ，拥有GMP车间满足高品质多元需求，并配备全国五大仓储中心。研发投入超3亿元，建有化学、生物两大研发中心，每年推出超10,000种新产品，截至2025年10月拥有178项知识产权 ，产品SCI引用超25.3万篇，稳居国内科研试剂文献TOP3 。
战略立足全球，已在美国、德国等多地设5个公司布局 ，连续获《国家级专精特新“小巨人”企业》 、《中国化学试剂十强企业》 、《最受用户欢迎试剂品牌》 等荣誉，秉承“推动发现，推进科学”的理念，助力科研创新。